Hodgkin's disease of donor origin after allogeneic bone marrow transplantation for myelogeneous chronic leukemia.
Secondary malignancies (lymphomas, leukemias, and solid tumors) occurring after bone marrow transplantation are now more frequently reported, as the patients surviving the early phase of the graft and remaining free of their original disease are more numerous. Besides early Epstein-Barr virus-associated B-cell lymphoproliferative diseases, which are the most common type and most often of donor origin, few late-occurring lymphomas have been described that might represent a distinct entity. We report here a case of Hodgkin's disease developing 8 years after allogeneic bone marrow transplantation for chronic myelogeneous leukemia. Only two Hodgkin's diseases after allogeneic bone marrow transplantation have been reported in the literature so far. The case we report is of interest because of its donor origin and its association with Epstein-Barr virus infection.
Meignin
V
V
Department of Pathology, Hôpital Saint-Louis, Paris, France.
Devergie
A
A
Brice
P
P
Brison
O
O
Parquet
N
N
Ribaud
P
P
Cojean
I
I
Gaulard
P
P
Gluckman
E
E
Socie
G
G
Janin
A
A
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000627:therapeutic use; D006566:Herpesviridae Infections / Q000473:pathology / Q000635:transmission; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006689:Hodgkin Disease / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008479:Mediastinal Neoplasms / Q000209:etiology* / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000473:pathology; D014019:Tissue Donors; D014412:Tumor Virus Infections / Q000473:pathology / Q000635:transmission; D014916:Whole-Body Irradiation
D003520:Cyclophosphamide; D008727:Methotrexate